Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5887515 | Seminars in Arthritis and Rheumatism | 2015 | 27 Pages |
Abstract
This study provides evidence that subsetting using antibody markers in addition to extent of skin involvement may predict clinical outcomes better than skin or serology alone in SSc. These findings can inform ongoing efforts to define more robust SSc subsets compared to those based on the extent of skin involvement or serology alone.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Neha MD, Marie MD, MPH, Solène MSc, Mianbo MSc, Murray MD, Marvin J. PhD, MD, Canadian Scleroderma Research Group (CSRG) Canadian Scleroderma Research Group (CSRG),